David Mazzo J.'s most recent trade in Lisata Therapeutics Inc was a trade of 81,000 Common Stock done . Disclosure was reported to the exchange on Jan. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 81,000 | 295,152 (2%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 09 Jan 2025 | 10,925 | 274,813 (2%) | 0% | 3.8 | 41,515 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 09 Jan 2025 | 9,414 | 285,738 (2%) | 0% | 3.8 | 35,773 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.80 per share. | 09 Jan 2025 | 7,017 | 267,796 (2%) | 0% | 3.8 | 26,665 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.73 per share. | 09 Jan 2025 | 3,106 | 264,690 (2%) | 0% | 3.7 | 11,585 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 2.93 per share. | 01 Oct 2024 | 58,000 | 238,798 (2%) | 0% | 2.9 | 169,940 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 01 Oct 2024 | 26,964 | 211,834 (1%) | 0% | 2.9 | 79,005 | Common Stock |
| Lisata Therapeutics Inc | J. Mazzo David | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.99 per share. | 11 Jan 2024 | 1,026 | 174,766 (1%) | 0% | 3.0 | 3,068 | Common Stock |
| Lisata Therapeutics Inc | J. Mazzo David | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 94,000 | 199,308 (1%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | Mazzo David J. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 47,000 | 47,000 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 09 Jan 2024 | 12,203 | 187,105 (1%) | 0% | 3.1 | 37,585 | Common Stock |
| Lisata Therapeutics Inc | David Mazzo J. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 09 Jan 2024 | 7,843 | 179,262 (1%) | 0% | 3.1 | 24,156 | Common Stock |
| Lisata Therapeutics Inc | David Mazzo J. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 09 Jan 2024 | 3,470 | 175,792 (1%) | 0% | 3 | 10,410 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.65 per share. | 13 Jan 2023 | 397 | 96,543 (0%) | 0% | 3.6 | 1,449 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 11 Jan 2023 | 1,030 | 96,940 (0%) | 0% | 3.2 | 3,296 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 60,000 | 109,285 (1%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.00 per share. | 09 Jan 2023 | 7,845 | 101,440 (0%) | 0% | 3 | 23,535 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 09 Jan 2023 | 3,470 | 97,970 (0%) | 0% | 3.2 | 11,087 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.50 per share. | 01 Sep 2022 | 150,000 | 809,186 (7%) | 1% | 0.5 | 75,000 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.50 per share. | 01 Sep 2022 | 69,742 | 739,444 (6%) | 0% | 0.5 | 34,871 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.82 per share. | 13 Jan 2022 | 6,611 | 631,065 (5%) | 0% | 0.8 | 5,424 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.81 per share. | 13 Jan 2022 | 6,471 | 637,676 (5%) | 0% | 0.8 | 5,218 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 401,000 | 717,297 (6%) | 3% | 0 | Common Stock | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.92 per share. | 10 Jan 2022 | 56,410 | 660,887 (6%) | 0% | 0.9 | 51,728 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.87 per share. | 10 Jan 2022 | 16,740 | 644,147 (6%) | 0% | 0.9 | 14,482 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2021 | 39,000 | 333,653 (3%) | 0% | 0 | Common Stock | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.55 per share. | 13 Jan 2021 | 21,787 | 311,866 (2%) | 0% | 1.6 | 33,770 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.55 per share. | 13 Jan 2021 | 6,425 | 305,441 (2%) | 0% | 1.6 | 9,959 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.56 per share. | 13 Jan 2021 | 5,936 | 299,505 (2%) | 0% | 1.6 | 9,260 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 119,000 | 311,274 (2%) | 1% | 0 | Common Stock | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 60,000 | 60,000 | - | - | Stock Options (Right to Buy) | |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.59 per share. | 08 Jan 2021 | 16,621 | 294,653 (2%) | 0% | 1.6 | 26,427 | Common Stock |
| Lisata Therapeutics Inc | David J. Mazzo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.60 per share. | 08 Jan 2021 | 4,726 | 192,274 (1%) | 0% | 1.6 | 7,562 | Common Stock |